Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice on February ...

Proposed $1.0 Million Convertible Debenture and Warrant Financing and Concurrent Common Share Private Placement Up to $1.0 Million Intended to Support Near-Term Operations ...

The Put Option Agreement was previously disclosed by Psyence BioMed and forms part of the broader strategic and commercial relationship between the two vertically integrated companies, including ...

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug ...

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that Henriette Mersebach will step down as Executive Vice President, Research and Development, and as a member of the Board of Management, ...

To schedule a 1x1 meeting with the Company, please contact your Leerink Partners institutional sales representative.

Bluejay Diagnostics (NASDAQ: BJDX) today announced that as of February 19, 2026, all of the prefunded warrants issued by the Company in its October 2025 private placement have been fully exercised, ...

YWECARE, an Australia-wide NDIS service provider founded by 25-year-old entrepreneur Mahmoud Khatib, is now supporting more than 100 participants across Sydney, Melbourne, and surrounding regions — ...

The clinically meaningful benefit seen with giredestrant could enable an important new treatment option to help delay disease progression or death in people with advanced, ER-positive breast cancer,” ...

Following the launch of SYNICEM™ antibiotic loaded preformed spacers in the UK last year, Biocomposites was already planning to follow this up with the launch of their SYNICEM™ bone cements. This UK ...

ALK expects to continue its trajectory of double-digit revenue growth and higher earnings in 2026. The EBIT margin is planned to remain in line with ALK’s long-term earnings ambitions reflecting that ...

Summit Pharmaceuticals International Corp. to serve as exclusive distributor for cell culture supplements in Japanese Market. The agreement marks PL BioScience’s first exclusive distribution ...